LivaNova PLC (NASDAQ:LIVN) updated its FY17 earnings guidance on Thursday. The company provided earnings per share guidance of $3.30-3.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.24.

A number of analysts recently issued reports on the company. Berenberg Bank reissued a buy rating and set a $70.00 price objective on shares of LivaNova PLC in a report on Friday, August 11th. Needham & Company LLC assumed coverage on LivaNova PLC in a report on Wednesday, August 23rd. They set a hold rating on the stock. Canaccord Genuity reissued a hold rating and set a $71.00 price objective on shares of LivaNova PLC in a report on Wednesday, September 20th. WBB Securities cut LivaNova PLC from a hold rating to a sell rating and set a $50.00 price objective on the stock. in a report on Tuesday, August 15th. Finally, BidaskClub cut LivaNova PLC from a buy rating to a hold rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. LivaNova PLC has an average rating of Hold and a consensus target price of $71.50.

LivaNova PLC (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.17. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The business had revenue of $309.70 million for the quarter, compared to the consensus estimate of $301.22 million. During the same period in the previous year, the business earned $0.78 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $68.55, for a total transaction of $68,550.00. Following the transaction, the director now owns 57,296 shares of the company’s stock, valued at $3,927,640.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 3,000 shares of company stock worth $203,890 over the last three months. 0.28% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at

About LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with's FREE daily email newsletter.